Enovis (NYSE:ENOV) Insider Oliver Engert Buys 1,000 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were acquired at an average price of $22.22 per share, with a total value of $22,220.00. Following the purchase, the insider owned 49,640 shares of the company’s stock, valued at $1,103,000.80. The trade was a 2.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Oliver Engert also recently made the following trade(s):

• On Friday, March 13th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were acquired at an average price of $23.74 per share, with a total value of $23,740.00.
• On Monday, March 9th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were acquired at an average price of $23.39 per share, with a total value of $23,390.00.
• On Friday, March 6th, Oliver Engert bought 750 shares of Enovis stock. The shares were acquired at an average price of $24.41 per share, with a total value of $18,307.50.

Enovis Price Performance

Shares of NYSE ENOV opened at $21.53 on Thursday. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. Enovis Corporation has a twelve month low of $20.82 and a twelve month high of $36.82. The stock has a 50 day moving average of $24.00 and a two-hundred day moving average of $24.85. The stock has a market cap of $1.24 billion, a P/E ratio of -1.08 and a beta of 1.38.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. During the same quarter in the previous year, the business earned $0.81 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts forecast that Enovis Corporation will post 3.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Front Street Capital Management Inc. grew its holdings in Enovis by 106.1% during the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after acquiring an additional 384,124 shares during the period. Amundi grew its holdings in Enovis by 2.3% during the first quarter. Amundi now owns 74,184 shares of the company’s stock worth $1,688,000 after acquiring an additional 1,677 shares during the period. California State Teachers Retirement System grew its holdings in Enovis by 38.9% during the first quarter. California State Teachers Retirement System now owns 76,966 shares of the company’s stock worth $1,751,000 after acquiring an additional 21,571 shares during the period. Quantinno Capital Management LP grew its holdings in Enovis by 130.8% during the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after acquiring an additional 342,556 shares during the period. Finally, London Co. of Virginia grew its holdings in Enovis by 12.0% during the first quarter. London Co. of Virginia now owns 416,582 shares of the company’s stock worth $9,477,000 after acquiring an additional 44,610 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ENOV. Needham & Company LLC boosted their price objective on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Enovis in a report on Friday, May 22nd. William Blair started coverage on shares of Enovis in a research report on Friday, April 17th. They issued an “outperform” rating for the company. Wells Fargo & Company reduced their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Evercore restated an “outperform” rating and issued a $36.00 price objective on shares of Enovis in a research report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $44.50.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.